Spero Therapeutics Inc (SPRO) has a current Price-to-Book (P/B) ratio of 4.99. Compared to its 3-year average P/B ratio of 1.70, the current P/B ratio is approximately 193.57% higher. Relative to its 5-year average P/B ratio of 2.25, the current P/B ratio is about 122.01% higher. Spero Therapeutics Inc (SPRO) has a Forward Free Cash Flow (FCF) yield of approximately -20.90%. Compared to its 3-year average FCF yield of -15.67%, the current FCF yield is approximately 33.42% lower. Relative to its 5-year average FCF yield of -40.05%, the current FCF yield is about -47.80% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SPRO competitors is 11.61, providing a benchmark for relative valuation. Spero Therapeutics Inc Corp (SPRO.O) exhibits a P/S ratio of 18.98, which is 63.46% above the industry average. Given its robust revenue growth of -59.60%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SPRO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SPRO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SPRO currently overvalued or undervalued?

What is Spero Therapeutics Inc (SPRO) fair value?

SPRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Spero Therapeutics Inc (SPRO) is between 0.77 to 2.58 according to relative valuation method.

How does SPRO's valuation metrics compare to the industry average?

The average P/S ratio for SPRO's competitors is 11.61, providing a benchmark for relative valuation. Spero Therapeutics Inc Corp (SPRO) exhibits a P/S ratio of 18.98, which is 63.46% above the industry average. Given its robust revenue growth of -59.60%, this premium appears unsustainable.

What is the current P/B ratio for Spero Therapeutics Inc (SPRO) as of Mar 05 2026?

As of Mar 05 2026, Spero Therapeutics Inc (SPRO) has a P/B ratio of 4.99. This indicates that the market values SPRO at 4.99 times its book value.

What is the current FCF Yield for Spero Therapeutics Inc (SPRO) as of Mar 05 2026?

As of Mar 05 2026, Spero Therapeutics Inc (SPRO) has a FCF Yield of -20.90%. This means that for every dollar of Spero Therapeutics Inc's market capitalization, the company generates -20.90 cents in free cash flow.

What is the current Forward P/E ratio for Spero Therapeutics Inc (SPRO) as of Mar 05 2026?

As of Mar 05 2026, Spero Therapeutics Inc (SPRO) has a Forward P/E ratio of 4.92. This means the market is willing to pay $4.92 for every dollar of Spero Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Spero Therapeutics Inc (SPRO) as of Mar 05 2026?

As of Mar 05 2026, Spero Therapeutics Inc (SPRO) has a Forward P/S ratio of 18.98. This means the market is valuing SPRO at $18.98 for every dollar of expected revenue over the next 12 months.

SPRO Valuation